Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Choy

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated ChondrosarcomaYin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Journal of Surgical Oncology|June 27, 2020
Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicityBrian C Baumann, Karen De Amorim Bernstein, Thomas F DeLaney, et al.
Nature Communications|August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumorsGaylor Boulay, Liliane C Broye, Rui Dong, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
American Journal of Human Genetics|March 16, 2007
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levelsDavid Reich, Nick Patterson, Vijaya Ramesh, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomasSam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue SarcomaChristopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 14, 2023
Prognostic Significance of Percentage and Size of Dedifferentiation in Dedifferentiated ChondrosarcomaYin P Hung, Ivan Chebib, Miriam A Bredella, et al.
Journal of Surgical Oncology|June 27, 2020
Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicityBrian C Baumann, Karen De Amorim Bernstein, Thomas F DeLaney, et al.
Nature Communications|August 28, 2024
EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumorsGaylor Boulay, Liliane C Broye, Rui Dong, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
American Journal of Human Genetics|March 16, 2007
Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levelsDavid Reich, Nick Patterson, Vijaya Ramesh, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomasSam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue SarcomaChristopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Pageof 18